Tuesday 8th September 2009 - Adelaide, Australia: Bionomics Limited today announced that it has satisfied one of the two outstanding conditions of its Subscription Agreement with Start-up Australia Ventures Pty Ltd (“Start-up”) for its $7 million investment in the Company, and has raised an additional $8 million.
As previously announced, one of the two conditions of the Start-up investment was Bionomics raising a further $5 million through private placements to institutional and sophisticated investors. This condition has been satisfied with the raising of $5.8 million. The only remaining condition will be satisfied when shareholders approve the issue of shares to Start-up at a shareholder meeting to be convened as soon as possible.
The placement price was 24 cents per share, as against the volume weighted average price of Bionomics shares for the 5 day period prior to and including 2 September of 24.03 cents.
The Company has reserved approximately 15% of the capital raising for participation by all shareholders through a Share Purchase Plan (“SPP”), at the same issue price as that offered to institutional and sophisticated investors. The SPP has been fully underwritten by LINWAR Securities Pty Ltd. LINWAR also acted as manager to the placement. The record date for the SPP will be Monday 14 September 2009 and, on the basis of a T Plus 3 settlement, the last date for purchasing shares to participate in the SPP will be Wednesday 9 September. Further details on the SPP will be provided to shareholders in a separate announcement.
In the absence of new opportunities or major developments, the Directors have committed not to raise further equity capital for at least two years.
In announcing the capital raising, the Company also announces that Chairman Dr Peter Jonson intends to retire from the board at the end of the Company’s Annual General Meeting in November. Mr Chris Fullerton, who joined the board in December 2008, will assume the role of Chairman at that time.
Dr Jonson commented “I am delighted with this significant, new capital raising and by the confidence of Bionomics’ shareholders in the potential of BNC105 and BNC210. Both drugs are targeting very serious medical conditions and I am very pleased to have played a role in fostering their development during my five years as Chairman”.
Mr Fullerton said “All shareholders owe Peter our gratitude and thanks for his sound leadership of the Board over a period which saw Bionomics transformed into a substantial, well funded company. His strategic input was instrumental in Bionomics identifying and completing two key acquisitions, both of which have had a critical impact on the Company’s development”.
FOR FURTHER INFORMATION PLEASE CONTACT:
P: +61 3 9866 4722 M: 0405 342 490
Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 / 0418 160 425
About Bionomics Limited
Bionomics (ASX: BNO) discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. Bionomics' most advanced program, BNC105 for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, the company's angiogenesis target and drug discovery platform, incorporates a variety of genomics tools to identify and validate novel angiogenesis targets. MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system.
For more information about Bionomics, visit www.bionomics.com.au